Core business
Diagnostic information services provider with 2025 net revenues of $11.0 billion
Source evidence
“During 2025, we generated net revenues of $11.0 billion.”

DGX
Updated: 03/11/2026, 21:00:32
No historical data available
Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum to reach a broad spectrum of clients. Its extensive client base includes patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and other direct healthcare entities. Delivery of these services is facilitated through a robust network comprising laboratories, patient service centers, in-office phlebotomists, call centers, and mobile health professionals including paramedics and nurses. Additionally, the company provides risk assessment services for the life insurance industry and offers comprehensive information technology solutions to healthcare organizations and clinicians.
No summaries found.
Reported and calculated KPIs plus operational exposure disclosed in the FY 2025 filing.
Revenue
$11.0B
FY 2025 · Reported
Net income
$1.0B
FY 2025 · Reported
Gross margin
33.2%
FY 2025 · Calculated
Free cash flow
$1.4B
FY 2025 · Calculated
R&D intensity
N/A
FY — · Reported
Share repurchases
$0.5B
FY 2025 · Reported
| Product / service | Sales | Share of sales | YoY growth | By reported area |
|---|---|---|---|---|
ds_revenue_change_pctSource evidence“DS revenues for the year ended December 31, 2025 decreased by 3.3% compared to the prior year primarily due to lower revenues associated with our risk assessment services offered to insurers.” | -3.3 | N/A | N/A | Not disclosed by product and area |
Other offerings mentioned without separate sales
Area-level product sales are displayed only when the filing reports a product × geography breakdown. Regional totals are not allocated across products by estimation.
Map layer
Pins show disclosed operations. The heatmap colors the filing’s reported geographies; regional figures shade the region and are not estimates for each country.
Only locations and quantities explicitly supported by the filing are displayed. A country-level manufacturing percentage or product allocation is shown only when the source discloses it; materiality scores are never presented as production shares.
Core business
Diagnostic information services provider with 2025 net revenues of $11.0 billion
“During 2025, we generated net revenues of $11.0 billion.”
Industry structure and growth outlook
Fragmented, highly competitive DIS industry; essential healthcare service expected to grow over the long term amid uncertain US healthcare regulation
“The diagnostic information services industry remains fragmented, is highly competitive and is subject to new competition.”
Diagnostic Information Services (DIS)
DIS provides diagnostic insights from lab testing to physicians, hospitals, patients/consumers, health plans, employers, government agencies, pharma companies and labs
“Our diagnostic information services ("DIS") business provides diagnostic insights from the results of our laboratory testing to empower people, physicians, and organizations to take action to improve health outcomes.”
Diagnostic Solutions (DS)
DS includes risk assessment services for insurers and healthcare IT solutions for providers and payers
“Our Diagnostic Solutions ("DS") group, which represents the balance of our consolidated net revenues, includes our risk assessment services business, which offers solutions for insurers, and our healthcare information technology businesses, which offer solutions for healthcare providers and payers.”
Primary customer channels
Primary channels: physicians, hospitals, patients/consumers; other channels include health plans, employers, retail healthcare, government, pharma companies
“Our growth strategy is focused on our primary customer channels – physicians, hospitals, patients and consumers – supported by Advanced Diagnostics™ (defined below), strategic acquisitions, and continuous quality improvement.”
Government and Medicare Advantage exposure
Growth in Medicare Advantage and Medicaid managed care; government arrangements for outbreak preparedness
“There has been growth of health insurance providers offering Medicare Advantage programs and of beneficiary enrollment in these programs.”
Patient service centers and consumer platform
2,400 patient service centers, many in retail settings; QuestHealth.com consumer-initiated testing platform with 150+ tests
“Many of our 2,400 patient service centers are located inside large retail stores or in convenient retail settings.”
Collaborative Lab Solutions
~$800 million in 2025 revenues/management fees from Collaborative Lab Solutions hospital lab outsourcing
“In 2025, our Collaborative Lab Solutions (formerly known as Professional Laboratory Services) offering generated approximately $800 million in revenues and management fees supporting hospitals in the operation of their own labs.”
Hospital reference testing
~$1.2 billion of 2025 revenue from hospital reference testing
“In 2025, we generated approximately $1.2 billion in revenue from "reference testing," where we perform testing that hospitals do not perform in their own in-hospital labs.”
Advanced Diagnostics
Advanced Diagnostics offerings in five clinical areas generated over $1 billion in 2025 revenues on double-digit growth
“In 2025, certain Advanced Diagnostics™ test offerings within five clinical areas – oncology, cardiometabolic and endocrine, brain health, autoimmune, women's health and genetics – generated over $1 billion in revenues on double-digit revenue growth.”
Geographic focus
Principally focused on U.S. market while serving customers globally with growing international reference testing
“While we principally focus on the U.S. market, we serve customers globally and have a growing business that provides advanced reference testing to laboratory providers in other countries.”
Net revenues by segment 2023-2025
Net revenues: $11,035M (2025), $9,872M (2024), $9,252M (2023); DIS: $10,785M / $9,614M / $8,976M; DS: $250M / $258M / $276M
“Net revenues$11,035$9,872$9,252 DIS revenues$10,785$9,614$8,976”
FY2025 DS revenue decline driven by risk assessment services
DS revenues -3.3% YoY primarily due to lower risk assessment services revenues offered to insurers
“DS revenues for the year ended December 31, 2025 decreased by 3.3% compared to the prior year primarily due to lower revenues associated with our risk assessment services offered to insurers.”
Employee base
Nearly 57,000 employees globally as of Dec 31, 2025; fewer than 1% of U.S. employees union-represented
“As of December 31, 2025, we have nearly 57,000 employees globally (including LifeLabs’ approximately 6,800), of whom approximately 46,000 are full-time and the remainder are part-time or on-call.”
Acquisition of select testing assets of Spectra Laboratories
Acquired select clinical testing and dialysis-related water testing assets of Spectra Laboratories (Fresenius Medical Care) for $84 million aggregate cash; closed August and November 2025; included in DIS
“We paid $84 million of aggregate cash consideration for the businesses. The acquired businesses are included in our DIS business.”
LifeLabs acquisition impact on revenue per requisition
LifeLabs acquisition has lower revenue per requisition, offsetting gains from tests per requisition and test mix
“favorable test mix were offset by the impact of the acquisition of LifeLabs, which has a lower revenue per requisition.”
Competitive landscape
Competes with commercial clinical labs, hospital-affiliated labs, physician-office labs, regional/local labs, specialized advanced labs, and consumer-initiated testing providers
“We primarily compete with three types of clinical testing providers: commercial clinical laboratories, hospital-affiliated laboratories and physician-office laboratories.”
Main competitors
Industry fragmented and highly competitive; largest commercial lab competitor is LabCorp
“Our largest commercial clinical laboratory competitor is Laboratory Corporation of America Holdings, Inc.”
Healthcare industry consolidation among customers
Rapid healthcare consolidation among customers; may encourage internalization of clinical testing and increase pricing transparency
“Consolidation in the healthcare industry has continued at a rapid pace, including among our customer base.”
Hospital market challenges as demand driver
Hospital cost pressure, consolidation and capital needs drive demand for Quest's lab expertise and services
“We believe that the market challenges faced by hospitals, including continued consolidation, price transparency, cost and utilization pressure, evolving healthcare payment models, capital needs, changing technology and limited resources, provide us with an opportunity to partner with them”
Competitive advantage
Believed competitive advantages include comprehensive test menu, scale, lower cost structure and integrated IT solutions
“We believe that as a large diagnostic information services provider we can serve our customers more effectively due to our larger network and lower cost structure.”
Invigorate program
Invigorate targets 3% annual cost savings and productivity improvements; 2025 restructuring/integration pre-tax charges of $53M including $28M employee separation costs
“The Invigorate program aims to deliver 3% annual cost savings and productivity improvements to partially offset pressures from an inflationary environment, including labor and benefit cost increases and reimbursement pressures.”
Growth strategy pillars
Growth via test menu breadth, broad access, data assets/value-based care, and Quest Management System with AI/automation
“continuously improving our quality and efficiency by leveraging the Quest Management System and by embracing innovative technologies, such as automation and artificial intelligence ("AI")”
Invigorate cost savings and productivity program
Invigorate program delivering cost savings and productivity improvements offsetting cost increases
“partially offset by cost savings and productivity improvements from our Invigorate program.”
Business restructuring and integration via workforce reductions
$62M FY2024 charges for workforce reductions and integration from restructuring and integrating the business
“primarily associated with workforce reductions and integration costs incurred in connection with further restructuring and integrating our business”
FY2025 cost of services increase drivers
Cost of services +$742M, driven by acquisitions, wage increases, higher supplies, partially offset by Invigorate savings
“Cost of services increased by $742 million for the year ended December 31, 2025 compared to the prior year. The increase was primarily driven by the impact of recent acquisitions, wage increases, and, to a lesser extent, higher supplies expense, partially offset by cost savings and productivity improvements from our Invigorate program.”
Inflationary cost pressures
Inflation raising costs of testing equipment, supplies, and goods/services purchased from manufacturers and suppliers
“On-going inflationary pressures have resulted in increases in the cost of our operations, including the costs of testing equipment, supplies and other goods and services we purchase from manufacturers, suppliers and others.”
FY2025 SG&A increase drivers
SG&A +$197M driven by acquisitions, compensation costs, and depreciation
“SG&A increased by $197 million for the year ended December 31, 2025 compared to the prior year. The increase was primarily driven by the impact of recent acquisitions and, to a lesser extent, higher compensation costs and higher depreciation expense.”
Industry reimbursement and utilization trends
Key trends: cost control/reimbursement pressure, fee-for-service to capitation shift, rising patient responsibility increasing price concession reserves, ACOs and spend management utilities
“In recent years, there has been an ongoing trend of rising patient responsibility which has resulted in an increase in our reserves for patient price concessions.”
Healthcare system evolution and value-based reimbursement shift
Value-based reimbursement is increasing and CMS has set goals for value-based reimbursement to be achieved by 2030; care is shifting to non-traditional venues and technologies
“value-based reimbursement is increasing (e.g., UnitedHealthcare's Preferred Lab Network) and CMS has set goals for value-based reimbursement to be achieved by 2030”
FY2024 items reducing diluted EPS by $1.24
FY2024 net items decreased diluted EPS by $1.24, incl. $127M amortization (-$0.84) and $62M restructuring/integration charges (-$0.42)
“pre-tax amortization expense of $127 million (recorded in amortization of intangible assets), or $0.84 per diluted share;”
FY2025 EPS-affecting items including CARES Act credit and gains
FY2025 items included CARES Act payroll tax credit, $8M lease gain, $10M contingent consideration gain (+$0.09), $4M strategic investment gains, $18M excess tax benefits (+$0.16)
“payroll tax credit under the Coronavirus Aid, Relief, and Economic Security Act ("CARES Act") associated with the retention of employees and an $8 million non-recurring gain related to a lease;”
Medicare CLFS and PAMA
PAMA Medicare cuts delayed through 2026; 2025 Results Act would reform PAMA toward a market-based CLFS
“Starting in 2020, Congress has repeatedly acted to delay PAMA implementation by delaying the next round of data reporting (2020-2026) and Medicare cuts (2021-2026). Congress introduced legislation in 2025, the Results Act, which would reform PAMA and create a true market-based CLFS.”
Reimbursement and utilization pressure from government payers
Government payers (Medicare, Medicaid) are taking steps to reduce utilization and reimbursement of clinical testing services, including increased prior authorization requirements
“We face efforts by government payers to reduce utilization of and reimbursement for diagnostic information services. One example of this is increased use of prior authorization requirements.”
Highly competitive fragmented clinical testing market
Clinical testing is fragmented and highly competitive; DGX competes with commercial labs, hospital-affiliated labs, physician-office labs, and new entrants such as employers and government agencies
“The clinical testing business remains a fragmented and highly competitive industry. We primarily compete with three types of clinical testing providers: other commercial clinical laboratories, including smaller regional and local commercial clinical laboratories and specialized advanced laboratories, hospital-affiliated laboratories and physician-office laboratories.”
Workforce constraints for skilled lab personnel
Supply of qualified technical personnel including cytotechs, phlebotomists and specimen processors is currently constrained; competition for employees is intense
“The supply of qualified technical, professional, managerial and other personnel, including cytotechs, phlebotomists and specimen processors, is currently constrained; competition for qualified employees, even across different industries, is intense”
Cybersecurity and IT system breach risk
IT systems have been and are subject to potential cyberattacks; third-party providers (e.g., AMCA 2019 breach) are also vectors; expanded use of AI may further expose systems
“Our IT systems have been and are subject to potential cyberattacks, tampering or other security breaches.”
Third-party payer pressure and health plan consolidation
Health plans have consolidated, resulting in fewer but larger plans with significant bargaining power; increased prior authorization, denials, and consumer-driven/high deductible plans
“The healthcare industry has experienced a trend of consolidation among health insurance plans, resulting in fewer but larger insurance plans with significant bargaining power to negotiate fee arrangements with us and other clinical testing providers.”
PAMA Medicare rate cuts and reform efforts
PAMA reimbursement cuts 2018-2020 exceeded original 10-year savings projections; Congress delayed implementation repeatedly; Results Act introduced in 2025 to reform PAMA
“Pursuant to PAMA, reimbursement rates for many clinical laboratory tests provided under Medicare were reduced during 2018 - 2020.”
Hospital ownership of physician practices strengthens hospital lab competitive position
Increased hospital ownership of physician practices may enhance clinician ties to hospital-affiliated laboratories, strengthening their competitive position
“There has been a trend of hospitals acquiring physician practices, increasing the percentage of physician practices owned by hospitals.”
Natural disaster, pandemic, and geopolitical operational disruption
Extreme weather, natural disasters, public health emergencies, pandemics, and geopolitical conflicts may limit or interrupt operations and specimen transport
“The ability of our employees and consumers to access our facilities may be adversely impacted by the effects of extreme weather events and natural disasters, such as hurricanes, earthquakes, tropical storms, floods, fires, or other extreme weather conditions”
Technology disruption risk including AI, digital pathology, point-of-care and home testing
Competitors may use advanced technology including AI-enabled technology and digital pathology; point-of-care and home testing could reduce demand for commercial lab services
“Competitors may compete using advanced technology, including technology that enables more convenient or cost-effective testing (e.g., technology enabled by AI). Digital pathology is an example of this.”
Acquisition and integration risk
Business development activities (acquisitions, licensing, investments, alliances, joint ventures) are inherently risky; integration may disrupt business and fail to realize expected benefits
“We plan selectively to enhance our business from time to time through business development activities, such as acquisitions, licensing arrangements, investments and alliances, including joint ventures.”
New test/technology development and licensing risk
Success depends on ability to develop or license new and improved technologies on favorable terms; failure would leave services outdated versus competition
“We may be unable to develop, introduce or commercialize new solutions or services.”
Medicare Advantage growth and state Medicaid pressures
Federal government expanded contracts with private health insurance plans (Medicare Advantage); state budget pressures may delay payments and reduce reimbursement
“the federal government has expanded its contracts with private health insurance plans for Medicare beneficiaries, called “Medicare Advantage” programs”
Consumer-initiated testing partnership regulatory risk
Arrangements with consumer health new entrants expose DGX to regulatory risks including CLIA, unlicensed and corporate practice of medicine laws, reimbursement uncertainty of direct-to-consumer health services
“These companies are operating in a new, rapidly evolving and uncertain regulatory landscape that subjects them to several risks, including those related to application of regulatory requirements (e.g., under CLIA, for testing performed outside of a commercial laboratory)”
Quality standards and reputation risk
Failure to assure appropriate quality standards in diagnostic information services could adversely affect operations and reputation
“The provision of diagnostic information services”
Physicians are a primary customer channel; Quest serves approximately half of U.S. physicians each year across primary care and specialties.
“We serve approximately half the physicians in the United States each year.”
Consolidated health plans with greater bargaining power can demand discounted fee structures or capitated arrangements, pressuring DGX reimbursement.
“Health plans, and independent physician associations, may demand that clinical testing providers accept discounted fee structures or assume all or a portion of the financial risk associated with providing testing services to their members through capitated payment arrangements.”
PAMA-based Medicare CLFS rate cuts directly reduce DGX reimbursement; delayed future cuts (2021-2026) and possible Results Act reform materially affect future revenue.
“Congress has repeatedly acted to delay PAMA implementation by delaying the next round of data reporting (2020-2026) and Medicare cuts (2021-2026).”
Hospitals generate reference testing revenue (~$1.2B) and Collaborative Lab Solutions fees (~$800M); hospital outreach acquisitions and JVs deepen this channel.
“We serve approximately half the hospitals in the United States each year”
PAMA reduced Medicare clinical lab reimbursement 2018-2020; further cuts delayed 2021-2026; Results Act could reform the fee schedule, directly affecting DIS pricing.
“Pursuant to The Protecting Access to Medicare Act of 2014 ("PAMA"), reimbursement rates for many clinical laboratory tests provided under Medicare were reduced during 2018 - 2020.”
DIS revenue growth is driven by both organic growth and recent acquisitions, with acquisitions contributing ~6.7% to revenue and ~8.9% to volume.
“The increase in DIS revenues compared to the prior year was driven by both organic growth and the impact of recent acquisitions.”
Hospitals compete for outreach testing and increasing hospital ownership of physician practices may redirect testing away from commercial labs.
“Increased hospital ownership of physician practices may enhance clinician ties to hospital-affiliated laboratories, even encouraging or requiring the practices they own to refer testing to the hospital's laboratory, strengthening their competitive position further.”
Constrained supply of cytotechs, phlebotomists, and specimen processors plus unionization activity could disrupt operations and raise labor costs.
“The supply of qualified technical, professional, managerial and other personnel, including cytotechs, phlebotomists and specimen processors, is currently constrained”
Capitated arrangements grew to ~8% of 2025 consolidated net revenues and ~15% of testing volume, exposing revenue to predetermined per-member rates regardless of services provided.
“There could be a shift to capitation arrangements where we agree to a predetermined monthly reimbursement rate for each member enrolled in a restricted plan.”
LabCorp is Quest's largest commercial clinical laboratory competitor in a fragmented, highly competitive industry.
“Our largest commercial clinical laboratory competitor is Laboratory Corporation of America Holdings, Inc.”
Legislative, enforcement, regulatory and public policy changes at federal or state level could adversely affect services offered and results of operations; uncertain political environment.
“The political environment impacting healthcare regulation in the United States continues to be uncertain.”
Competitors may use AI-enabled technology and digital pathology for more convenient or cost-effective testing, threatening DGX volumes; DGX's own AI use also expands cyberattack surface.
“Competitors may compete using advanced technology, including technology that enables more convenient or cost-effective testing (e.g., technology enabled by AI).”
Inflation increases operating costs including testing equipment and supplies, which the Invigorate program's 3% annual savings target is designed to partially offset.
“The Invigorate program aims to deliver 3% annual cost savings and productivity improvements to partially offset pressures from an inflationary environment, including labor and benefit cost increases and reimbursement pressures.”
Wage increases were a primary driver of the $742M cost of services increase, indicating wage growth as a material cost driver.
“The increase was primarily driven by the impact of recent acquisitions, wage increases, and, to a lesser extent, higher supplies expense”
Quest competes with commercial labs, hospital-affiliated labs, physician-office labs, and consumer-initiated testing providers in a fragmented, highly competitive industry.
“We primarily compete with three types of clinical testing providers: commercial clinical laboratories, hospital-affiliated laboratories and physician-office laboratories.”
Hurricanes, earthquakes, floods, pandemics, and geopolitical conflicts may interrupt facility access, specimen transport, and supply receipt across DGX's primarily US-based facility network.
“such events may limit or interrupt our ability to conduct operations. Additionally, such events may interrupt our ability to transport specimens, to receive materials from our suppliers or otherwise to provide our services.”
DGX provides underlying testing for consumer health new entrants whose regulatory landscape (CLIA, unlicensed/corporate practice of medicine laws, DTC reimbursement uncertainty) creates legal and reputational exposure.
“unlicensed and corporate practice of medicine laws that differ across the United States, reimbursement uncertainty of direct-to-consumer health services”
Testing orders are affected by changes in the economy and regulatory environment affecting the number of unemployed and uninsured, and by healthcare plan design changes affecting utilization and patient responsibility.
“orders for clinical testing generated from customers, including physicians, hospitals, and consumers, can be affected by factors such as changes in the economy and regulatory environment”
Growth of consumer-initiated testing and demand for health/wellness services positions Quest's consumer offerings (QuestHealth.com, retail PSCs) for expanding opportunities.
“our consumer focus positions us to capture expanding opportunities presented by the growth of consumer-initiated testing and of the demand for expanded access to health and wellness services”
Medicare Advantage enrollment growth and Medicaid managed care mandates shift payer mix toward private government-sponsored programs; government arrangements also support outbreak preparedness testing.
“There has been growth of health insurance providers offering Medicare Advantage programs and of beneficiary enrollment in these programs.”
Quest is leveraging automation and AI to improve productivity and quality across its value chain as part of the Invigorate program.
“We are leveraging automation and artificial intelligence to improve productivity and also improve quality across our entire value chain, not just in the laboratory.”
Emerging technologies such as digital pathology, point-of-care testing and home testing could displace central lab testing volumes.
“including point-of-care testing that can be administered by physicians in their offices, complex testing that can be performed by hospitals in their own laboratories, and home testing that can be carried out without requiring the services of providers like us.”
DS segment revenues declined 3.3% due to lower risk assessment services revenues from insurers, showing insurer exposure in DS.
“primarily due to lower revenues associated with our risk assessment services offered to insurers.”
Testing volumes and cash flows decline during vacation/holiday periods and from severe weather or public health emergencies, creating recurring intra-year revenue variability.
“Testing volume is also subject to declines due to severe weather or other events (such as public health emergencies and health pandemics)”
Quest's efficiency strategy depends on embracing automation and AI within the Quest Management System.
“continuously improving our quality and efficiency by leveraging the Quest Management System and by embracing innovative technologies, such as automation and artificial intelligence ("AI")”
Higher supplies expense contributed to the FY2025 cost of services increase.
“and, to a lesser extent, higher supplies expense, partially offset by cost savings”
See which prediction-market events move DGX, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Quest Diagnostics (DGX) Upgraded to Buy: Here's What You Should Know
Zacks Investment Research • STOCK • 29/05/2026, 15:01:10
Here's Why Quest Diagnostics (DGX) is a Strong Value Stock
Zacks Investment Research • STOCK • 28/05/2026, 12:40:40
Are Medical Stocks Lagging Quest Diagnostics (DGX) This Year?
Zacks Investment Research • STOCK • 26/05/2026, 12:40:35
Why Is Quest Diagnostics (DGX) Down 5% Since Last Earnings Report?
Zacks Investment Research • STOCK • 21/05/2026, 14:31:32
Quest Diagnostics Declares Quarterly Cash Dividend
PRNewsWire • STOCK • 19/05/2026, 18:37:00
Is This the Right Time to Hold DGX Stock in Your Portfolio?
Zacks Investment Research • STOCK • 19/05/2026, 12:30:40
Bullish Quarterly Results: 3 Companies Raising Guidance
Zacks Investment Research • STOCK • 07/05/2026, 21:45:11
Quest Diagnostics: Updating Levels After Q1 Earnings
Seeking Alpha • STOCK • 07/05/2026, 17:40:08
Why Quest Diagnostics (DGX) is a Top Value Stock for the Long-Term
Zacks Investment Research • STOCK • 06/05/2026, 12:41:30
Quest Diagnostics Prices $500 Million of Senior Notes
PRNewsWire • STOCK • 27/04/2026, 18:10:00
Here's Why Quest Diagnostics (DGX) is a Strong Momentum Stock
Zacks Investment Research • STOCK • 22/04/2026, 12:51:20
Quest Diagnostics Incorporated (DGX) Q1 2026 Earnings Call Transcript
Seeking Alpha • STOCK • 21/04/2026, 13:20:38